Time-To-Loss Of Virologic Response Acceptable Endpoint For HIV Drugs-FDA
Executive Summary
Traditional approval of antiretroviral drugs may be based on clinical trials using a primary endpoint of time-to-loss of virologic response or on an endpoint of the proportion of patients whose HIV RNA levels fall below the acceptable assay level, a draft guidance released by FDA states.
You may also be interested in...
HIV Trials Should Focus On Pre-Treated Patients, FDA Guidance Says
FDA is encouraging sponsors of HIV therapies to conduct more clinical trials in treatment-experienced patients
HIV Trials Should Focus On Pre-Treated Patients, FDA Guidance Says
FDA is encouraging sponsors of HIV therapies to conduct more clinical trials in treatment-experienced patients
HIV "Salvage" Drug Efficacy May Be Shown With Half-Log Drop In Viral Load
A .5-log drop in viral load may be an optimal endpoint for testing "salvage" therapies in treatment-experienced HIV patients, FDA's Antiviral Drugs Advisory Committee concluded.